GSK's $2.2B purchase of Rapt Therapeutics

On this episode of Stock Movers:
- French luxury group LVMH is on track for a seventh straight session of losses, the longest streak since March, after US President Donald Trump signaled he could impose a 200% tariff on French wines and champagne.
- Ferretti’s second-largest investor is preparing to propose a shareholder vote to oust directors with connections to the yacht maker’s top owner, China’s Weichai Group, according to people familiar with the matter.
- GSK agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and immunologic diseases, in a deal valued at $2.2 billion.

See omnystudio.com/listener for privacy information.